

Address Mailed Label No.

Dated: \_\_\_\_\_

Docket No.: 05432/000J951-US0

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Connie Sánchez et al.

Confirmation No.: 7268

Application No.: 10/021,126

Art Unit: 1614

Filed: December 12, 2001

Examiner: F. Krass

For: Treatment of Neurotic Disorders

**RECEIVED**  
DEC 03 2003  
TECH CENTER 1600/2900

**RESPONSE**

MS Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed August 21, 2003, kindly consider the following remarks.

Claims 1-5, 10, 11, and 14 have been rejected under 35 U.S.C. §102(b) as anticipated by Lepola et al. (*J. Clin. Psychiatry*, 59:10, pp.528-534 (October 1998)). Lepola discloses the use of racemic citalopram to treat panic attacks. The Examiner contends that because the pending claims do not specify any optical purity and include the open-ended transitional phrase "comprising", they do not exclude the inclusion of the (-) isomer and, therefore, read on racemic citalopram.

12/01/2003 WASFAW1 00000031 10021126

02 FC:1806

180.00 0P

{W:\05432\000J951-US0\00088069.DOC [REDACTED]}

The pending claims are directed to a method of treating a neurotic disorder, such as panic attacks, by administering an effective amount of escitalopram.

A racemic mixture is a 1:1 mixture of (+) and (-) enantiomers. See the definition of "racemic" in Exhibit A. Therefore, racemic citalopram as disclosed in Lepola is a 1:1 mixture of the (+) or S-enantiomer of citalopram and the (-) or R-enantiomer of citalopram. In contrast, the term "escitalopram" refers to the S-enantiomer of citalopram. See the last paragraph on page 1 of the present application. In *In re May*, 574 F.2d 1082 (CCPA 1978), the predecessor court to the Court of Appeals for the Federal Circuit held that a claim reciting the levo enantiomer does not read on a racemate of the same compound. *Id.* at 1090 ("the novelty of an optical isomer is not negated by the prior art disclosure of its racemate"). A copy of the *In re May* decision is submitted herewith as Exhibit B. Similarly, escitalopram refers to the S-enantiomer of citalopram and does not encompass the racemate of citalopram. Therefore, claims 1-5, 10, 11, and 14 are not anticipated by Lepola. Accordingly, applicants respectfully request withdrawal of this rejection.

Claims 1-5, 10, 11, and 14 have been rejected under 35. U.S.C. §103(a) as obvious over Lepola in view of Boegesoe et al. (U.S.P. 4,943,950). Claims 12 and 13 have been rejected under 35. U.S.C. §103(a) as obvious over Lepola.

The Examiner contends that Boegesoe teaches that the activity of citalopram resides entirely in the (+) isomer (col.2, lines 38-40), and that it would, therefore, have been obvious to use the (+) isomer of citalopram, rather than racemic citalopram to treat panic attacks as disclosed by Lepola.

Submitted herewith as Exhibit C is an article entitled “R-Citalopram Attenuates Anxiolytic Effects of Escitalopram in a Rat Ultrasonic Vocalisation Model” which was recently



In normal rats, citalopram only partially inhibited ultrasonic vocalization (64% inhibition), while escitalopram nearly completely inhibited the response (97% inhibition). See the column entitled "Drug (30 min), s.c." in Table 1. When the basal levels of 5-HT in rats were increased by administering L-5-HTP (25 mg/kg), the median effective dose (ED<sub>50</sub>) of citalopram was twice as much as that needed to obtain maximum inhibition in a normal rat. In contrast, the median effective dose of escitalopram in rats having enhanced levels of 5-HT was one-tenth (<sup>1</sup>/<sub>10</sub>) that needed to obtain maximum inhibition in a normal rat. In other words, escitalopram exhibits greater potency in rats with increased 5-HT levels than in rats at normal 5-HT levels, while citalopram exhibits decreased potency. Furthermore, escitalopram was about 20-times more potent than citalopram in the rats with enhanced 5-HT basal levels.

The ability of R-citalopram to attenuate (or reduce) the therapeutic effect of escitalopram was tested further by comparing the footshock-induced ultrasonic vocalisation in rats dosed with escitalopram alone and those dosed with escitalopram (0.24 mg/kg) and R-citalopram (0.48 mg/kg) concomitantly. Based on the test results shown in the insert of Figure 1 on page 156, Sánchez concluded that "[t]he addition of R-citalopram significantly attenuated the inhibitory effect of escitalopram on footshock-induced ultrasonic vocalization" (left column, last full paragraph, page 157).

These results demonstrate that R-citalopram attenuates the anxiolytic effect of escitalopram in footshock-induced ultrasonic vocalisation.

This is especially surprising because "it would be expected that R-citalopram's histamine H<sub>1</sub> receptor antagonistic activity would enhance rather than attenuate the effect of




If there are any other issues remaining which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

Dated: November 21, 2003

Respectfully submitted,

By

  
Jay P. Lessler

Registration No.: 41,151

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys For Applicants